Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 2/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.48 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.45 |
| ▸ | SMO | Q99835 | 2/20 | 0.44 |
| ▸ | GHSR | Q92847 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23040234 | 1.00 | MMP1 (0.48) | MMP1MMP3MMP9EHMT2SMO | |
| SCHEMBL10134835 | 1.00 | MMP1 (0.48) | MMP1MMP3MMP9EHMT2SMO | |
| SCHEMBL11959439 | 1.00 | MMP1 (0.48) | MMP1MMP3MMP9EHMT2SMO | |
| SCHEMBL23040054 | 1.00 | MMP1 (0.48) | MMP1MMP3MMP9EHMT2SMO | |
| SCHEMBL14607231 | 1.00 | MMP1 (0.48) | MMP1MMP3MMP9EHMT2SMO | |
| SCHEMBL23040273 | 0.89 | MMP1 (0.46) | MMP1MMP3MMP9EHMT2SMO | |
| SCHEMBL29270895 | 0.89 | MMP1 (0.46) | MMP1MMP3MMP9EHMT2SMO | |
| SCHEMBL23040155 | 0.89 | MMP1 (0.46) | MMP1MMP3MMP9EHMT2SMO | |
| SCHEMBL29270897 | 0.89 | MMP1 (0.46) | MMP1MMP3MMP9EHMT2SMO | |
| SCHEMBL3557914 | 0.88 | MMP1 (0.54) | MMP1MMP3MMP9EHMT2SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119033-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| EP-4380936-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BeiGene, Ltd. (KY) | 2024-06-12 | — | — | EP | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| WO-2023011456-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | BEIGENE, LTD. (KY) | 2023-02-09 | — | — | WO | disclosed |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| EP-2699562-B1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-7799789-B2 | Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2010-09-21 | — | — | US | disclosed |
| US-7786124-B2 | Heterocyclic substituted pyridine compounds with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100168124-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION | 2010-07-01 | — | — | US | disclosed |
| WO-2009079490-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20080292589-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION | 2008-11-27 | — | — | US | disclosed |
| US-7417045-B2 | Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity | SCHERING CORPORATION (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080058343-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080039474-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| WO-2007109238-A1 | HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070054919-A1 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058343-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, ACKR3 | MMP1 1199/4885MMP3 2108/4885MMP9 2031/4885 |
| US-20070054919-A1 | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity | CXCR3, CXCR1, CCR5 | MMP1 1314/4885MMP3 2420/4885MMP9 2317/4885 |
| US-20080292589-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE OR PHENYL COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, CCR1 | MMP1 1662/4885MMP3 2677/4885MMP9 2314/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | MMP1 4554/4885MMP3 4132/4885MMP9 2565/4885 |
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | MMP1 3473/4885MMP3 2668/4885MMP9 915/4885 |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | MMP1 4554/4885MMP3 4132/4885MMP9 2565/4885 |
| US-20100168124-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, CXCL10 | MMP1 1697/4885MMP3 2849/4885MMP9 2449/4885 |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | MMP1 4554/4885MMP3 4132/4885MMP9 2565/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | MMP1 3473/4885MMP3 2668/4885MMP9 915/4885 |
| US-20080039474-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, ACKR3 | MMP1 1924/4885MMP3 2991/4885MMP9 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.